THSNA Virtual Meeting

Announcement
Thank you for attending THSNA 2026. The virtual meeting is now closed.

Posters/Exhibits/Break > Session

Posters/Exhibits/Break

Presentations

A1. ANTICOAGULATION CLINICS
				(300) ANTICOAGULATION STEWARDSHIP IN THE REAL-WORLD SETTING Nghi Ha, Denise Sutter-Long, Anisa Bici, Erin Mouland, Elizabeth Renner. Michigan Medicine, Ann Arbor, MI, USA
A4. DISORDERS OF PLATELET NUMBER OR FUNCTION
				(301) MODIFIED DURABLE PLATELET RESPONSE BY INTERNATIONAL WORKING GROUP CRITERIA: LUNA3 PHASE 3 STUDY OF RILZABRUTINIB VS PLACEBO IN ADULTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA Waleed Ghanima¹, Yoshitaka Miyakawa², Nichola Cooper³, Marie Luise Hütter-Krönke⁴, Maria Cristina Pascual Izquierdo⁵, Sylvain Audia⁶, Meredith C. Foster⁷, Maria Belen Rodriguez⁷, Jing Zhao⁷, Ahmed Daak⁷, David J. Kuter⁸, David Farber⁷. ¹Østfold Hospital Trust, Grålum, Norway and Institute of Clinical Medicine, University of Oslo, Oslo, Norway ²Department of Hematology, Saitama Medical University, Saitama, Japan ³Hammersmith Hospital, London, United Kingdom ⁴Department of Hematology, Oncology and Tumorimmunology, Charité - Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany ⁵Department of Hematology, Gregorio Marañon Hospital, Madrid, Spain ⁶CHU Dijon Bourgogne - Hopital Francois Mitterrand, Dijon, France ⁷Sanofi, Cambridge, MA, USA ⁸Hematology Division, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
				(302) IDENTIFICATION OF A PROPOSED NOVEL PATHOGENIC MYH-9 MUTATION IN A FAMILY WITH DUAL DIAGNOSIS OF VON WILLEBRAND DISEASE AND SUSPECTED MYH9-RELATED DISEASE Kawana Simon¹, Radha Vyas¹, Colleen Ciccosanti². ¹Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA ²Division of Hematology, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA
A5. BLOOD COAGULATION AND FIBRINOLYTIC FACTORS
				(303) VALIDATION OF THE FIIX ASSAY ON WERFEN ACL TOP 750 ANALYZER A Eshaghpour¹, K Moffat^1,2, S Carlino², L Letertre³, E Belley-Cote¹, D.M Witt⁴, B Gudmundsdottir³, P Onundarson^3,5, M Crowther¹. ¹Department of Medicine, McMaster University, Hamilton, ON, Canada ²Hamilton Regional Laboratory Medicine Program, Hamilton, ON, Canada ³Departments of Medicine and Laboratory Medicine, Landspitali National University of Iceland, Reykjavik, Iceland ⁴University of Utah College of Pharmacy, Salt Lake City, UT, USA ⁵Faculty of Medicine, University of Iceland, Reyjkavik, Iceland
				(304) PERIOPERATIVE HEMOSTATIC STRATEGIES IN TOTAL KNEE ARTHROPLASTY FOR HEMOPHILIA: A SYSTEMATIC EVIDENCE REVIEW OF BLEEDING, FACTOR USE, AND THROMBOTIC RISK Jack Russek¹, Angad Thakral². ¹Touro University California, Vallejo, CA, USA ²Touro University California, Vallejo, CA, USA
A6. DISORDERS OF COAGULATION OR FIBRINOLYSIS
				(305) MAJOR DENTAL SURGERIES CONDUCTED UNDER FITUSIRAN PROPHYLAXIS IN PEOPLE WITH HEMOPHILIA A AND B, WITH AND WITHOUT INHIBITORS Suchitra S Acharya¹, Laurent Frenzel², Kaan Kavakli³, Teh-Liane Khoo⁴, László Nemes⁵, Jing Sun⁶, Te-Fu Weng⁷, Chur-Woo You⁸, Salim Kichou⁹, Abhimanyu Yarramaneni¹⁰, Laurel A Menapace¹⁰, Yuqian Shen¹⁰, Ezio Zanon¹¹. ¹Northwell Health, New York, NY, USA ²Groupe Hospitalier Necker Enfants Malades, Paris, France ³Ege University Faculty of Medicine, Izmir, Turkey ⁴Royal Prince Alfred Hospital, Sydney, Australia ⁵Central Hospital of Northern Pest – Military Hospital, Budapest, Hungary ⁶Nanfang Hospital, Guangzhou, China ⁷Chung Shan Medical University Hospital, Taichung, Taiwan ⁸Eulji University Hospital, Daejeon, South Korea ⁹Sanofi Genzyme, Paris, France ¹⁰Sanofi, Cambridge, MA, USA ¹¹Azienda Ospedale Università di Padova, Padua, Italy
				(306) CONCIZUMAB EFFICACY IN PATIENTS WITH HEMOPHILIA A/B WITHOUT INHIBITORS FROM THE PHASE 3 EXPLORER8 STUDY: A POST-HOC SENSITIVITY ANALYSIS FOR THE INTRA-PATIENT COMPARISON OF CONCIZUMAB WITH PREVIOUS PROPHYLAXIS Anthony KC Chan¹, Hermann Eichler², Julien Bovet³, Renée Brown Frandsen³, Allison P Wheeler⁴, Emily Waters⁵, Pratima Chowdary⁶, Leandra LePorte⁵. ¹Department of Pediatrics, McMaster Children's Hospital, McMaster University, Hamilton, ON, Canada ²Institute of Clinical Hemostaseology and Transfusion Medicine, Saarland University and University Hospital, Homburg, Germany ³Novo Nordisk A/S, Søborg, Denmark ⁴Division of Pediatric Hematology/Oncology & Division of Hematology and Oncology, University of Washington School of Medicine, Seattle, WA, USA ⁵Novo Nordisk Inc., Plainsboro, NJ, USA ⁶Katharine Dormandy Haemophilia and Thrombosis Centre, Royal Free London NHS Foundation Trust, and Department of Haematology, Cancer Institute, University College London, London, United Kingdom
				(307) COMBINED FACTOR V AND FACTOR VIII DEFICIENCY ASSOCIATED WITH COMPOUND HETEROZYGOUS LMAN1 VARIANTS: A CASE REPORT Rida Haider ^{1, 2}, Natalie Montanez^{1, 3}, Joanna Larson^{1, 3}, Harish Eswaran^{1, 4}, Miguel Escobar^{1, 4}. ¹Gulf States Hemophilia and Thrombophilia Center, Houston, TX, USA ²University of Texas Health Science Center of Houston, McGovern Medical School, Department of Pediatrics, Division of Medical Genetics, Houston, TX, USA ³University of Texas Health Science Center of Houston, McGovern Medical School, Department of Pediatrics, Division of Hematology, Houston, TX, USA ⁴University of Texas Health Science Center of Houston, McGovern Medical School, Department of Pediatrics and Internal Medicine, Division of Hematology, Houston, TX, USA
				(308) UPDATE ON A NOVEL INVESTIGATIONAL ADENO-ASSOCIATED VIRUS GENE THERAPY, SPK-8011QQ: RATIONALE AND DESIGN OF A PHASE IIB TRIAL Andrew D. Leavitt¹, Alice Cohen², M. Elaine Eyster³, Kristina Haley⁴, Akshat Jain⁵, Daniel J. Lee⁶, Maddalena Marchesi⁷, Catherine McGuinn⁸, Nicolas Receveur⁷, Michael Recht ⁹, Amit Soni ¹⁰, Sasha Sreckovic¹¹, Miles Viljanen¹¹. ¹Departments of Medicine and of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA ²Newark Beth Israel Medical Center, Newark, NJ, USA ³Penn State Hershey Medical Center, Hershey, PA, USA ⁴Hemostasis and Thrombosis Center, Oregon Health and Science University, Portland, OR, USA ⁵Department of Pediatrics, Division of Hematology/Oncology, Loma Linda University School of Medicine, Loma Linda, CA, USA ⁶Department of Hematology/Oncology, Kaiser Permanente, Vallejo/Vacaville, CA, USA ⁷F. Hoffmann-La Roche Ltd, Basel, Switzerland ⁸Department of Pediatrics, Weill Cornell Medicine College, New York, NY, USA ⁹Hemophilia Treatment Center and Pediatric Hematology-Oncology, Yale University School of Medicine, New Haven, CT, USA ¹⁰Center for Inherited Blood Disorders, Orange, CA, USA ¹¹Genentech, Inc., South San Francisco, CA, USA
				(309) APOLD1-ASSOCIATED VASCULAR-TYPE BLEEDING DISORDER PRESENTING WITH SEVERE POSTOPERATIVE HEMORRHAGE: A CASE REPORT Natalie Montanez ^{1, 2}, Rida Haider ^{1, 3}, Joanna Larson^{1, 2}, Harish Eswaran^{1, 4}, Miguel Escobar^{1, 4}. ¹Gulf States Hemophilia and Thrombophilia Center, Houston, TX, USA ²University of Texas Health Science Center of Houston, McGovern Medical School, Department of Pediatrics, Division of Hematology, Houston, TX, USA ³University of Texas Health Science Center of Houston, McGovern Medical School, Department of Pediatrics, Division of Medical Genetics, Houston, TX, USA ⁴University of Texas Health Science Center of Houston, McGovern Medical School, Department of Pediatrics and Internal Medicine, Division of Hematology, Houston, TX, USA
				(310) SIXTH INTERIM ANALYSIS OF THE HEM-POWR STUDY: EVALUATING REAL-WORLD EFFECTIVENESS AND SAFETY OF DAMOCTOCOG ALFA PEGOL IN PATIENTS WITH SEVERE AND NONSEVERE HEMOPHILIA A IN THE UNITED STATES Mark T Reding¹, Beng Fuh², Vanessa Salinas³, Maissaa Janbain⁴. ¹Center for Bleeding and Clotting Disorders, University of Minnesota, Minneapolis, MN, USA ²East Carolina University, Greenville, NC, USA ³Center for Inherited Blood Disorders, Orange, CA, USA ⁴Tulane School of Medicine, New Orleans, LA, USA
				(311) BILIARY EVENTS IN THE FITUSIRAN CLINICAL DEVELOPMENT PROGRAM WITH THE ANTITHROMBIN-BASED DOSE REGIMEN Mindy Simpson¹, Canan Albayrak², Savita Rangarajan^3,4, Oleksandra Stasyshyn⁵, Jing Sun⁶, Chur-Woo You⁷, Abhimanyu Yarramaneni⁸, Laurel A. Menapace⁸, Yuqian Shen⁸, Kaan Kavakli⁹. ¹Rush Hemophilia and Thrombophilia Center, Rush University Medical Center, Chicago, IL, USA ²Ondokuz Mayis University Faculty of Medicine, Department of Pediatric Hematology, Samsun, Turkey ³Advanced Centre for Oncology, Haematology and Rare Diseases, K.J. Somaiya Super Specialty Hospital, Mumbai, India ⁴Faculty of Medicine, University of Southampton, Southampton, United Kingdom ⁵Institute of Blood Pathology and Transfusion Medicine, Lviv ⁶Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China ⁷Department of Pediatrics, Eulji University School of Medicine, Seoul, Korea ⁸Sanofi, Cambridge, MA ⁹Division of Hematology, Department of Pediatrics, Ege University Faculty of Medicine, Izmir, Turkey
				(312) THE ROLE OF VON WILLEBRAND FACTOR IN SICKLE CELL DISEASE CHRONIC ORGAN DAMAGE Marta Wolosowicz¹, Tomasz Kaminski¹, Ayyanar Sivanantham¹, Nicholas Swendrowski¹, Nandhine Rajasekhar¹, Tirthadipa Pradhan-Sundd^{1, 2}. ¹Versiti Blood Research Institute, Milwaukee, WI, USA ²Medical College of Wisconsin, Wauwatosa, WI, USA
A7. PATHOPHYSIOLOGY OF THROMBOSIS
				(313) MOBILE PATIENTS MISS AND REFUSE MORE DOSES OF VENOUS THROMBOEMBOLISM (VTE) PROPHYLAXIS Brandyn D. Lau^1,2,3,4, Erik H. Hoyer^1,2, Dauryne L. Shaffer⁵, Peggy S. Kraus⁵, Elliott R. Haut^1,2,3,4, Michael B. Streiff^1,2. ¹Johns Hopkins School of Medicine, Baltimore, MD, USA ²Armstrong Institute for Patient Safety and Quality, Baltimore, MD, USA ³Welch Center for Prevention, Epidemiology, and Clinical Research, Baltimore, MD, USA ⁴Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA ⁵Johns Hopkins Hospital, Baltimore, MD, USA
A8. ANTITHROMBOTIC THERAPY
				(314) LOW RISK FOR MENINGOCOCCAL INFECTIONS WITH SYSTEMICALLY ADMINISTERED PEGCETACOPLAN, A COMPLEMENT C3 AND C3B INHIBITOR Carlos de Castro¹, Sheena Patel², Holly Snyder³, Peter Hillmen³. ¹Duke University, Durham, NC, USA ²Swedish Orphan Biovitrum AB, Stockholm, Sweden ³Apellis Pharmaceuticals, Inc, Waltham, MA, USA
				(315) APIXABAN VS RIVAROXABAN FOR VENOUS THROMBOEMBOLISM IN GASTROINTESTINAL CANCER: A SYSTEMATIC REVIEW AND META-ANALYSIS Ursula Medeiros Araujo de Matos¹, Pedro Luiz Lage Bodour Danielian², Moana Divina da SIlva Santiago¹, Nicole Sequeira¹. ¹Internal Medicine Department, University of Connecticut, Farmington, CT, USA ²Harvard T. H. Chan School of Public Health, Boston, MA, USA
				(316) MANAGEMENT AND OUTCOMES OF SUBTHERAPEUTIC WARFARIN ANTICOAGULATION IN PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME AND MECHANICAL MITRAL VALVES Sara R Vazquez^1,2, Stephen Short², Spencer Gilbert^1,2, Daniel M Witt^1,2. ¹University of Utah Health Thrombosis Service, Murray, UT, USA ²University of Utah College of Pharmacy, Salt Lake City, UT, USA
A9. INFORMATIONAL ABSTRACT (POSTER ONLY)
				(317) HEALTHCARE RESOURCE UTILIZATION IN PEOPLE WITH HEMOPHILIA TREATED WITHIN VS. EXTERNAL TO U.S. HEMOPHILIA TREATMENT CENTER NETWORK CLINICS: AN UPDATE FROM THE CHESS US STUDY Enrico Ferri Grazzi¹, Ming Lim², Nicole Crook³, Maria Santaella⁴, Michael Recht^4,5, Adam Giermasz⁶, Jonathan Roberts⁷, Randall Curtis⁸. ¹Federation of Hemophilia Associations (FedEmo), Milan, Italy ²University of Utah, Salt Lake City, UT, USA ³Center for Inherited Blood Disorders, Orange, CA, USA ⁴National Bleeding Disorders Foundation, New York, NY, USA ⁵Yale School of Medicine, New Haven, CT, USA ⁶University of California, Davis, CA, USA ⁷Bleeding & Clotting Disorders Institute, Peoria, IL, USA ⁸Factor VIII Computing, Walnut Creek, CA, USA
				(318) HIGH STAKES HEMOSTASIS: DESCRIBING RISKS OF TRIPLE ANTITHROMBOTIC THERAPY IN PATIENTS ON TEMPORARY MECHANICAL CIRCULATORY SUPPORT John Purdie, Eric B. Simpson, Zachary R. Smith, Mir B. Basir, Kristin Griebe, Benjamin A. August. Henry Ford Hospital, Detroit, MI, USA